John W. Davis, MD, Professor of Urology and Director of the Urosurgical Prostate Program at the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses how the Center is dealing with the COVID-19 crisis by setting up a committee to determine on a case-by-case basis which surgeries are to move forward, as well as which elective surgeries are still being performed. While trying to be cognizant of the need to conserve resources, the urology department is focusing primarily on large renal tumors and invasive bladder cancer. Overall, they have reduced the OR and ICU capacity to about 25% in order to make room for COVID-19 admissions. Dr. Davis also details the need to test all patients for COVID-19 prior to any elective surgery in order to lessen potential negative outcomes, self-quarantine for two weeks prior to surgery, and, if possible, delay surgery altogether in order to prevent an undiagnosed patient from infecting the OR team. This is particularly true in favorable, intermediate-risk cases that can be delayed anywhere from six months to a year without affecting outcomes.Read More
John W. Davis, MD
MD Anderson Cancer Center
John W. Davis, MD, is a Professor of Urology and Director of the Urosurgical Prostate Program at the University of Texas MD Anderson Cancer Center in Houston. He received his BS in Biology at Davidson College in North Carolina in 1990. He then went on to earn his Medical Degree at the University of Virginia in 1994 and completed his residency training at Eastern Virginia Graduate School of Medicine in Norfolk. Dr. Davis had fellowship training in prostate cancer research in the Department of Microbiology and Molecular Cell Biology at Eastern Virginia Medical School, and received an American Foundation of Urologic Disease Scholar award for proteomic applications in prostate cancer biomarkers. He completed a Clinical Fellowship in Urologic Oncology at the MD Anderson Cancer Center, and a Fellowship in Laparoscopic Urology at Charité Hospital in Berlin, Germany, under the mentorship of Ingolf Tuerk. Dr. Davis’ clinical interests include patients with urologic cancers, laparoscopic/robotic surgery, and general urology. His academic interests include quality of life after prostate cancer treatment, outcomes for robotic radical prostatectomy, high-risk prostate cancer trials, active surveillance for prostate cancer, and development of robotic surgical techniques for invasive bladder cancer. He has participated as an investigator in several Southwest Oncology Group and industry-sponsored clinical trials. Dr. Davis is board-certified by the American Board of Urology and is a member of several professional organizations, including the Society of Urologic Oncology, the Endourology Society, the Society of Robotic Surgeons, the Société Internationale d’Urologie, and the American Urological Association. He is also a Fellow of the American College of Surgeons. His leadership positions in professional societies have included President of the Young Urologic Oncologists (2003-2005) and President of the Society of Urologic Robotic Surgeons (2010-2012). He is the Treasurer for the South Central Section of the AUA, as well as the Online Content Editor for the AUA. His peer-reviewed publication involvement is highlighted by his role as Associate Editor for Urologic Oncology for the British Journal of Urology International.
Articles by John W. Davis, MD
Posted by John W. Davis, MD | Jun 2019
John W. Davis, MD, debates the pros of using <20mg/mL as a threshold for the optimal nadir level of serum testosterone in prostate cancer patients treated with ADT.Read More
Focal Therapy for Localized Prostate Cancer: Is There a “Middle Ground” Between Active Surveillance and Definitive Treatment?
Posted by John W. Davis, MD | May 2019
John W. Davis, MD, discusses the lack of consensus regarding the definitions and benefits of focal therapy for prostate cancer. He defines the patients who would benefit most from focal therapy, as well as overcoming current challenges in this approach.Read More
Posted by John W. Davis, MD | Jan 2019
John W. Davis, MD, provides instructions regarding how to build an effective handout for patients prior to robot assisted radical prostatectomy. Specifically, he describes commonly asked patient questions and how to answer in an evidence-based and trustworthy manner.Read More
Posted by John W. Davis, MD | Dec 2018
John W. Davis, MD, discusses the benefits and limitations of focal therapy for prostate cancer. He describes ways in which focal therapy can be a middle ground between active surveillance and standard therapies, as well as identifying appropriate candidates for this approach.Read More